These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 16103070)

  • 1. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model.
    Ali S; King GD; Curtin JF; Candolfi M; Xiong W; Liu C; Puntel M; Cheng Q; Prieto J; Ribas A; Kupiec-Weglinski J; van Rooijen N; Lassmann H; Lowenstein PR; Castro MG
    Cancer Res; 2005 Aug; 65(16):7194-204. PubMed ID: 16103070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits.
    King GD; Kroeger KM; Bresee CJ; Candolfi M; Liu C; Manalo CM; Muhammad AK; Pechnick RN; Lowenstein PR; Castro MG
    Mol Ther; 2008 Apr; 16(4):682-90. PubMed ID: 18283279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics.
    Puntel M; Muhammad AK; Candolfi M; Salem A; Yagiz K; Farrokhi C; Kroeger KM; Xiong W; Curtin JF; Liu C; Bondale NS; Lerner J; Pechnick RN; Palmer D; Ng P; Lowenstein PR; Castro MG
    J Virol; 2010 Jun; 84(12):6007-17. PubMed ID: 20375153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro.
    Candolfi M; Pluhar GE; Kroeger K; Puntel M; Curtin J; Barcia C; Muhammad AK; Xiong W; Liu C; Mondkar S; Kuoy W; Kang T; McNeil EA; Freese AB; Ohlfest JR; Moore P; Palmer D; Ng P; Young JD; Lowenstein PR; Castro MG
    Neuro Oncol; 2007 Jul; 9(3):245-58. PubMed ID: 17522335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
    Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
    Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central nervous system toxicity of two adenoviral vectors encoding variants of the herpes simplex virus type 1 thymidine kinase: reduced cytotoxicity of a truncated HSV1-TK.
    Cowsill C; Southgate TD; Morrissey G; Dewey RA; Morelli AE; Maleniak TC; Forrest Z; Klatzmann D; Wilkinson GW; Löwenstein PR; Castro MG
    Gene Ther; 2000 Apr; 7(8):679-85. PubMed ID: 10800091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenoviral-mediated gene transfer into the canine brain in vivo.
    Candolfi M; Kroeger KM; Pluhar GE; Bergeron J; Puntel M; Curtin JF; McNiel EA; Freese AB; Ohlfest JR; Moore P; Lowenstein PR; Castro MG
    Neurosurgery; 2007 Jan; 60(1):167-77; discussion 178. PubMed ID: 17228266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma.
    Candolfi M; Curtin JF; Yagiz K; Assi H; Wibowo MK; Alzadeh GE; Foulad D; Muhammad AK; Salehi S; Keech N; Puntel M; Liu C; Sanderson NR; Kroeger KM; Dunn R; Martins G; Lowenstein PR; Castro MG
    Neoplasia; 2011 Oct; 13(10):947-60. PubMed ID: 22028620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Efficacy of Immune Stimulatory Thymidine Kinase and fms-like Tyrosine Kinase 3 Ligand (TK/Flt3L) Gene Therapy in a Mouse Model of High-Grade Brainstem Glioma.
    Mendez F; Kadiyala P; Nunez FJ; Carney S; Nunez FM; Gauss JC; Ravindran R; Pawar S; Edwards M; Garcia-Fabiani MB; Haase S; Lowenstein PR; Castro MG
    Clin Cancer Res; 2020 Aug; 26(15):4080-4092. PubMed ID: 32332014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.
    Kamran N; Kadiyala P; Saxena M; Candolfi M; Li Y; Moreno-Ayala MA; Raja N; Shah D; Lowenstein PR; Castro MG
    Mol Ther; 2017 Jan; 25(1):232-248. PubMed ID: 28129117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression.
    Ghulam Muhammad AK; Candolfi M; King GD; Yagiz K; Foulad D; Mineharu Y; Kroeger KM; Treuer KA; Nichols WS; Sanderson NS; Yang J; Khayznikov M; Van Rooijen N; Lowenstein PR; Castro MG
    Clin Cancer Res; 2009 Oct; 15(19):6113-27. PubMed ID: 19789315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 2. Tumor-specific immunity and cure after radio-inducible suicide gene therapy and systemic CD40-ligand and Flt3-ligand gene therapy in an orthotopic tumor model.
    Kawashita Y; Deb NJ; Garg MK; Kabarriti R; Fan Z; Alfieri AA; Roy-Chowdhury J; Guha C
    Radiat Res; 2014 Aug; 182(2):201-10. PubMed ID: 24992166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.
    King GD; Muhammad AK; Curtin JF; Barcia C; Puntel M; Liu C; Honig SB; Candolfi M; Mondkar S; Lowenstein PR; Castro MG
    Neuro Oncol; 2008 Feb; 10(1):19-31. PubMed ID: 18079358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity.
    Candolfi M; Yagiz K; Foulad D; Alzadeh GE; Tesarfreund M; Muhammad AK; Puntel M; Kroeger KM; Liu C; Lee S; Curtin JF; King GD; Lerner J; Sato K; Mineharu Y; Xiong W; Lowenstein PR; Castro MG
    Clin Cancer Res; 2009 Jul; 15(13):4401-14. PubMed ID: 19570774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased invasion of malignant gliomas after 15-LO-1 and HSV-tk/ganciclovir combination gene therapy.
    Pacholska A; Wirth T; Samaranayake H; Pikkarainen J; Ahmad F; Ylä-Herttuala S
    Cancer Gene Ther; 2012 Dec; 19(12):870-4. PubMed ID: 23079672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Herpes simplex virus thymidine kinase gene therapy for rat malignant brain tumors.
    Vincent AJ; Vogels R; Someren GV; Esandi MC; Noteboom JL; Avezaat CJ; Vecht C; Bekkum DW; Valerio D; Bout A; Hoogerbrugge PM
    Hum Gene Ther; 1996 Jan; 7(2):197-205. PubMed ID: 8788170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved therapeutic effect on malignant glioma with adenoviral suicide gene therapy combined with temozolomide.
    Stedt H; Samaranayake H; Pikkarainen J; Määttä AM; Alasaarela L; Airenne K; Ylä-Herttuala S
    Gene Ther; 2013 Dec; 20(12):1165-71. PubMed ID: 24067866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term transgene expression within the anterior pituitary gland in situ: impact on circulating hormone levels, cellular and antibody-mediated immune responses.
    Southgate TD; Stone D; Williams JC; Lowenstein PR; Castro MG
    Endocrinology; 2001 Jan; 142(1):464-76. PubMed ID: 11145611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flt3L in Combination With HSV1-TK-mediated Gene Therapy Reverses Brain Tumor-induced Behavioral Deficits.
    King GD; Kroeger KM; Bresee CJ; Candolfi M; Liu C; Manalo CM; Muhammad AG; Pechnick RN; Lowenstein PR; Castro MG
    Mol Ther; 2008 Apr; 16(4):682-690. PubMed ID: 28178463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy in BT4C rat glioma model.
    Tyynelä K; Sandmair AM; Turunen M; Vanninen R; Vainio P; Kauppinen R; Johansson R; Vapalahti M; Ylä-Herttuala S
    Cancer Gene Ther; 2002 Nov; 9(11):917-24. PubMed ID: 12386830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.